PL1809271T3 - Zastosowania (R)-(halobenzyloksy)benzyloamino-propanamidów jako modulator kanałów sodowych i/lub wapniowych - Google Patents

Zastosowania (R)-(halobenzyloksy)benzyloamino-propanamidów jako modulator kanałów sodowych i/lub wapniowych

Info

Publication number: PL1809271T3
Authority: PL; Poland
Prior art keywords: halobenzyloxy; propanamides; benzylamino; sodium; calcium channel
Prior art date: 2004-09-10

Application number

PL05769799T

Other languages

English (en)

Inventor

Elena Barbanti

Florian Thaler

Carla Caccia

Ruggero Fariello

Patricia Salvati

Original Assignee

Newron Pharm Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-09-10

Filing date

2005-07-28

Publication date

2010-10-29

2005-07-28 Application filed by Newron Pharm Spa filed Critical Newron Pharm Spa

2010-10-29 Publication of PL1809271T3 publication Critical patent/PL1809271T3/pl

Links

YAIQLSGJDFUANQ-UHFFFAOYSA-N 2-(benzylamino)propanamide Chemical class NC(=O)C(C)NCC1=CC=CC=C1 YAIQLSGJDFUANQ-UHFFFAOYSA-N 0.000 title 1
108090000312 Calcium Channels Proteins 0.000 title 1
102000003922 Calcium Channels Human genes 0.000 title 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title 1
108010052164 Sodium Channels Proteins 0.000 title 1
102000018674 Sodium Channels Human genes 0.000 title 1
239000011734 sodium Substances 0.000 title 1
229910052708 sodium Inorganic materials 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Immunology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL05769799T 2004-09-10 2005-07-28 Zastosowania (R)-(halobenzyloksy)benzyloamino-propanamidów jako modulator kanałów sodowych i/lub wapniowych PL1809271T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP04021525		2004-09-10
EP05769799A EP1809271B9 (en)	2004-09-10	2005-07-28	Use of (r)-(halobenzyloxy) benzylamino-propanamides as sodium and/or calcium channel selective modulators
PCT/EP2005/008200 WO2006027052A2 (en)	2004-09-10	2005-07-28	(halobenzyloxy) benzylamino-propanamides as sodium and/or calcium channel selective modulators

Publications (1)

Publication Number	Publication Date
PL1809271T3 true PL1809271T3 (pl)	2010-10-29

Family

ID=34926488

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL05769799T PL1809271T3 (pl)	2004-09-10	2005-07-28	Zastosowania (R)-(halobenzyloksy)benzyloamino-propanamidów jako modulator kanałów sodowych i/lub wapniowych

Country Status (27)

Country	Link
US (2)	US20080096965A1 (pl)
EP (1)	EP1809271B9 (pl)
JP (1)	JP5319920B2 (pl)
KR (1)	KR101277520B1 (pl)
CN (1)	CN101018546B (pl)
AR (1)	AR050638A1 (pl)
AT (1)	ATE471147T1 (pl)
AU (1)	AU2005282028B2 (pl)
BR (1)	BRPI0515154A (pl)
CA (1)	CA2577408C (pl)
CY (1)	CY1110770T1 (pl)
DE (1)	DE602005021907D1 (pl)
DK (1)	DK1809271T5 (pl)
ES (1)	ES2347581T3 (pl)
HR (1)	HRP20100400T1 (pl)
IL (1)	IL181445A (pl)
ME (1)	ME01801B (pl)
MX (1)	MX2007002713A (pl)
NO (1)	NO338713B1 (pl)
NZ (1)	NZ553970A (pl)
PL (1)	PL1809271T3 (pl)
PT (1)	PT1809271E (pl)
RS (1)	RS51411B (pl)
RU (1)	RU2391973C2 (pl)
SI (1)	SI1809271T1 (pl)
TW (1)	TWI351950B (pl)
WO (1)	WO2006027052A2 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1423168T3 (da) *	2001-09-03	2006-05-15	Newron Pharm Spa	Farmaceutisk præparat omfattende gabapentin eller en analog deraf og et alfa-aminoamid og dets analgetiske anvendelse
EP1438956A1 (en) *	2003-01-16	2004-07-21	Newron Pharmaceuticals S.p.A.	Alpha-aminoamide derivatives useful as antimigraine agents
DK1658062T3 (da) *	2003-08-25	2010-05-31	Newron Pharm Spa	Alfa-aminoamid-derivater anvendelige som anti-inflammatoriske midler
DK1809271T5 (da) *	2004-09-10	2010-12-06	Newron Pharm Spa	Anvendelse af (R)-(halogenbenzyloxy)benzylaminopropanamider som natrium- og/eller calciumkanalselektive modulatorer
EP1963280B1 (en)	2005-12-22	2015-10-28	Newron Pharmaceuticals S.p.A.	2-phenylethylamino derivatives as calcium and/or sodium channel modulators
HUE030233T2 (en) *	2006-06-19	2017-04-28	Newron Pharm Spa	High purity 2- [4- (3- and 2-fluorobenzyloxy) benzylamino] propanamides for use as medicaments and pharmaceutical compositions containing them
CA2689561C (en)	2007-06-15	2015-11-17	Newron Pharmaceuticals S.P.A.	Substituted 2- [2- (phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
US8530701B2 (en) *	2007-12-11	2013-09-10	Newron Pharmaceuticals, S.P.A.	High purity 2-[4-(3- OR 2-fluorobenzyloxy)benzylamino]propanamides and methods of use thereof
NZ586182A (en) *	2007-12-19	2012-02-24	Newron Pharm Spa	Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders
WO2009109334A1 (en) *	2008-03-07	2009-09-11	Newron Pharmaceuticals S.P.A.	(s)-(+)-2-[4-fluorbenzyloxy)benzylamino]propanamide for use in the treatment of mixed or combined pain
US9549967B2 (en)	2009-05-29	2017-01-24	The University Of North Carolina At Chapel Hill	Regulation of sodium channels by PLUNC proteins
SI2563355T1 (sl) *	2010-04-27	2016-10-28	Newron Pharmaceuticals S.P.A.	Postopek za izdelavo metansulfonatnih soli ralfinamida ali njihovih R-enantiomerov
PT2723710T (pt)	2011-06-27	2016-11-14	Newron Pharm Spa	Derivados fluorados de arilalquilaminocarboxamida
MX2017004653A (es) *	2014-10-08	2017-10-16	Univ North Carolina Chapel Hill	Inhibidores peptidicos de canales de sodio mejorados.
PT3487839T (pt)	2017-06-20	2021-02-11	Raqualia Pharma Inc	Derivados de amida como bloqueadores de nav1.7 e nav1.8

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3451062A (en) *	1966-03-16	1969-06-24	Theodore Bradley	Disposable examination gown
US3658967A (en) *	1966-06-23	1972-04-25	Ici Ltd	Carboxylic acid derivatives for lowering the concentration of triglycerides in the blood
GB1140748A (en) *	1966-06-23	1969-01-22	Ici Ltd	New carboxylic acid derivatives
CH480308A (de) *	1966-08-11	1969-10-31	Ciba Geigy	Verfahren zur Herstellung von Thiosemicarbazid-Verbindungen
US4049663A (en) *	1972-06-06	1977-09-20	Allen & Hanburys Limited	Ethylene diamine derivatives
DE2460891C2 (de) *	1974-12-21	1982-09-23	Gödecke AG, 1000 Berlin	1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) *	1974-12-21	1978-05-02	Warner-Lambert Company	Treatment of cranial dysfunctions using novel cyclic amino acids
US4311853A (en) *	1979-02-06	1982-01-19	The Radiochemical Centre Limited	Selenium derivatives of thyroxine and tri-iodothyronine
DE3010599A1 (de) *	1979-03-22	1980-10-09	Continental Pharma	Derivate von glycinamid, deren herstellung und verwendung
US4267354A (en) *	1979-04-25	1981-05-12	E. R. Squibb & Sons, Inc.	Substituted amides having antiinflammatory activity and intermediates
DK153787C (da) *	1979-06-01	1989-01-16	Wellcome Found	Analogifremgangsmaade til fremstilling af substituerede 3,5-diamino-6-phenyl-1,2,4-triaziner og alfa-cyanobenzyliden-aminoguanidinforbindelser til anvendelse som mellemprodukter herved
FR2480747A1 (fr) *	1980-04-17	1981-10-23	Roques Bernard	Derives d'acides amines et leur application therapeutique
DE3483308D1 (de) *	1983-11-21	1990-10-31	Fujisawa Pharmaceutical Co	Semicarbazid-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
US4839369A (en) *	1985-04-16	1989-06-13	Rorer Pharmaceutical Corporation	Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4725619A (en) *	1985-04-16	1988-02-16	Usv Pharmaceutical Corporation	Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4631287A (en) *	1985-04-16	1986-12-23	Usv Pharmaceutical Corp.	Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
GB8714901D0 (en) *	1986-07-23	1987-07-29	Ici Plc	Amide derivatives
RU2070041C1 (ru) *	1988-03-04	1996-12-10	Киргизский государственный медицинский институт	Средство для стимуляции лейкопоэза
GB2216515A (en) *	1988-03-04	1989-10-11	Nippon Shinyaku Co Ltd	Acylphenol derivatives
US4894476A (en) *	1988-05-02	1990-01-16	Warner-Lambert Company	Gabapentin monohydrate and a process for producing the same
FR2639225B1 (fr) *	1988-11-21	1993-05-21	Centre Nat Rech Scient	Compositions pharmaceutiques pour la neuroprotection contenant des arylcyclohexylamines
IL94466A (en) *	1989-05-25	1995-01-24	Erba Carlo Spa	Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US5051403A (en) *	1989-11-22	1991-09-24	Neurex Corporation	Method of treating ischemia-related neuronal damage
US5025035A (en) *	1990-10-12	1991-06-18	Warner-Lambert Company	Method of treating depression
WO1993013128A1 (en) *	1991-12-30	1993-07-08	Neurex Corporation	Methods of producing analgesia and enhancing opiate analgesia
GB9203483D0 (en) *	1992-02-19	1992-04-08	Wellcome Found	Anti-inflammatory compounds
US5330515A (en) *	1992-06-17	1994-07-19	Cyberonics, Inc.	Treatment of pain by vagal afferent stimulation
US5256669A (en) *	1992-08-07	1993-10-26	Aminotek Sciences, Inc.	Methods and compositions for treating acute or chronic pain and drug addiction
US5498610A (en) *	1992-11-06	1996-03-12	Pfizer Inc.	Neuroprotective indolone and related derivatives
GB9306886D0 (en) *	1993-04-01	1993-05-26	Erba Carlo Spa	Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
GB9306899D0 (en) *	1993-04-01	1993-05-26	Erba Carlo Spa	Substituted (arylalkylaminobenzyl) aminopropionamide derivatives and process for their preparation
US5475007A (en) *	1993-05-28	1995-12-12	The Regents Of The University Of California	1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oximes and the use thereof
ZA953078B (en) *	1994-04-28	1996-01-05	Alza Corp	Effective therapy for epilepsies
US5482964A (en) *	1994-10-11	1996-01-09	Warner-Lambert Company	Substituted phenoxyhydroxypropyl amines as central nervous system agents
US5541204A (en) *	1994-12-02	1996-07-30	Bristol-Myers Squibb Company	Aryloxypropanolamine β 3 adrenergic agonists
GB9426102D0 (en) *	1994-12-23	1995-02-22	Merck Sharp & Dohme	Pharmacuetical compositions
KR0147963B1 (ko) *	1995-01-10	1998-08-17	강박광	엔-아릴알킬페닐아세트아미드 유도체와 그의 제조방법
GB9500691D0 (en) *	1995-01-13	1995-03-08	Smithkline Beecham Plc	Compounds
US5849737A (en) *	1995-04-14	1998-12-15	The Regents Of The University Of California	Compositions and methods for treating pain
US5741818A (en) *	1995-06-07	1998-04-21	University Of Saskatchewan	Semicarbazones having CNS activity and pharmaceutical preparations containing same
GB9512854D0 (en) *	1995-06-23	1995-08-23	Wellcome Found	Novel formulation
US5795864A (en) *	1995-06-27	1998-08-18	Neurex Corporation	Stable omega conopetide formulations
GB9515412D0 (en) *	1995-07-27	1995-09-27	Pharmacia Spa	2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
US5688830A (en) *	1996-01-25	1997-11-18	Syntex (U.S.A.) Inc.	Treatment of neuropathic pain
US6372792B1 (en) *	1996-04-26	2002-04-16	Guy Chouinard	Method for treating anxiety, anxiety disorders and insomnia
WO1998007447A1 (en) *	1996-08-23	1998-02-26	Algos Pharmaceutical Corporation	Anticonvulsant containing composition for treating neuropathic pain
US6290986B1 (en) *	1996-10-24	2001-09-18	Pharmaceutical Applications Associates, Llc	Method and composition for transdermal administration of pharmacologic agents
US6207685B1 (en) *	1996-12-06	2001-03-27	Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.)	Therapeutic application of a thienycyclohexylamine derivative
WO1998054123A1 (en) *	1997-05-30	1998-12-03	Warner-Lambert Company	Substituted peptidylamine calcium channel blockers
WO1999008670A1 (en) *	1997-08-20	1999-02-25	Guglietta, Antonio	Gaba analogs to prevent and treat gastrointestinal damage
IT1295423B1 (it) *	1997-10-10	1999-05-12	Medivis S R L	Uso della flunarizina nella terapia topica del glaucoma
EP1032377B1 (en) *	1997-11-21	2010-11-17	Purdue Neuroscience Company	Substituted 2-aminoacetamides and the use thereof
GB9727521D0 (en) *	1997-12-31	1998-02-25	Pharmacia & Upjohn Spa	Substituted 2-benzylamino-2-phenyl-acetamide compounds
GB9727523D0 (en) *	1997-12-31	1998-02-25	Pharmacia & Upjohn Spa	Alpha-aminoamide derivatives useful as analgesic agents
US5905069A (en) *	1998-01-26	1999-05-18	The General Hospital Corporation	Methods of decreasing or preventing pain using spicamycin or derivatives thereof
US6458781B1 (en) *	1998-04-27	2002-10-01	David Thomas Connor	Substituted diarylalkyl amides as calcium channel antagonists
SE9801494D0 (sv) *	1998-04-28	1998-04-28	Astra Pharma Prod	Novel use
US6011035A (en) *	1998-06-30	2000-01-04	Neuromed Technologies Inc.	Calcium channel blockers
EP1094817A1 (en) *	1998-07-09	2001-05-02	Warner-Lambert Company	Compositions comprising gaba analogs and caffeine
US6316440B1 (en) *	1998-07-30	2001-11-13	Warner-Lambert Company	Reduced dipeptide analogues as calcium channel antagonists
US6281211B1 (en) *	1999-02-04	2001-08-28	Euro-Celtique S.A.	Substituted semicarbazides and the use thereof
EP1200086A4 (en) *	1999-08-04	2009-05-27	Icagen Inc	THERAPEUTIC OR PROPHYLACTIC METHODS OF PAIN AND ANXIETY
AU7102700A (en) *	1999-09-22	2001-04-24	Ortho-Mcneil Pharmaceutical, Inc.	Benzo-fused dithiepino[6,5-b]pyridines, and related compositions and methods
US6113915A (en) *	1999-10-12	2000-09-05	Allergan Sales, Inc.	Methods for treating pain
WO2001070748A1 (en) *	2000-03-23	2001-09-27	Ortho-Mcneil Pharmaceutical, Inc.	THIEPINO [3,2-b] DIHYDROPYRIDINES AND RELATED COMPOSITIONS AND METHODS
US6521647B2 (en) *	2000-04-04	2003-02-18	Pfizer Inc.	Treatment of renal disorders
DK1423168T3 (da) *	2001-09-03	2006-05-15	Newron Pharm Spa	Farmaceutisk præparat omfattende gabapentin eller en analog deraf og et alfa-aminoamid og dets analgetiske anvendelse
SI1458386T1 (sl) *	2001-12-27	2007-08-31	Ortho Mcneil Pharm Inc	Aroil pirol heteroeril in metanoli, uporabni za zdravljenje motnje centralnega živčnega sistema
EP1438956A1 (en) *	2003-01-16	2004-07-21	Newron Pharmaceuticals S.p.A.	Alpha-aminoamide derivatives useful as antimigraine agents
WO2004066987A2 (en) *	2003-01-30	2004-08-12	Dynogen Pharmaceuticals, Inc.	Use of sodium channel modulators for treating gastrointestinal tract disorders
AU2004207010A1 (en) *	2003-01-30	2004-08-12	Dynogen Pharmaceuticals, Inc.	Methods of treating lower urinary tract disorders using sodium channel modulators
AR044007A1 (es) *	2003-04-11	2005-08-24	Newron Pharmaceuticals Inc	Metodos para el tratamiento de la enfermedad de parkinson
DK1658062T3 (da) *	2003-08-25	2010-05-31	Newron Pharm Spa	Alfa-aminoamid-derivater anvendelige som anti-inflammatoriske midler
EP1535908A1 (en) *	2003-11-24	2005-06-01	Newron Pharmaceuticals S.p.A.	N-acyl-N'-benzyl-alkylendiamino drivatives
EP1557166A1 (en) *	2004-01-21	2005-07-27	Newron Pharmaceuticals S.p.A.	Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
EP1588704A1 (en) *	2004-04-22	2005-10-26	Newron Pharmaceuticals S.p.A.	Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
DK1809271T5 (da) *	2004-09-10	2010-12-06	Newron Pharm Spa	Anvendelse af (R)-(halogenbenzyloxy)benzylaminopropanamider som natrium- og/eller calciumkanalselektive modulatorer

2005
- 2005-07-28 DK DK05769799.7T patent/DK1809271T5/da active
- 2005-07-28 CN CN2005800303817A patent/CN101018546B/zh not_active Expired - Lifetime
- 2005-07-28 ME MEP-2010-331A patent/ME01801B/me unknown
- 2005-07-28 SI SI200531091T patent/SI1809271T1/sl unknown
- 2005-07-28 CA CA2577408A patent/CA2577408C/en not_active Expired - Lifetime
- 2005-07-28 MX MX2007002713A patent/MX2007002713A/es active IP Right Grant
- 2005-07-28 NZ NZ553970A patent/NZ553970A/en not_active IP Right Cessation
- 2005-07-28 US US11/574,751 patent/US20080096965A1/en not_active Abandoned
- 2005-07-28 PT PT05769799T patent/PT1809271E/pt unknown
- 2005-07-28 AT AT05769799T patent/ATE471147T1/de active
- 2005-07-28 RS RSP-2010/0331A patent/RS51411B/sr unknown
- 2005-07-28 RU RU2007113190/15A patent/RU2391973C2/ru active
- 2005-07-28 KR KR1020077008185A patent/KR101277520B1/ko not_active Expired - Lifetime
- 2005-07-28 HR HR20100400T patent/HRP20100400T1/hr unknown
- 2005-07-28 ES ES05769799T patent/ES2347581T3/es not_active Expired - Lifetime
- 2005-07-28 WO PCT/EP2005/008200 patent/WO2006027052A2/en not_active Ceased
- 2005-07-28 PL PL05769799T patent/PL1809271T3/pl unknown
- 2005-07-28 BR BRPI0515154-6A patent/BRPI0515154A/pt not_active Application Discontinuation
- 2005-07-28 AU AU2005282028A patent/AU2005282028B2/en not_active Expired
- 2005-07-28 JP JP2007530600A patent/JP5319920B2/ja not_active Expired - Lifetime
- 2005-07-28 DE DE602005021907T patent/DE602005021907D1/de not_active Expired - Lifetime
- 2005-07-28 EP EP05769799A patent/EP1809271B9/en not_active Expired - Lifetime
- 2005-08-15 TW TW094127695A patent/TWI351950B/zh not_active IP Right Cessation
- 2005-09-09 AR ARP050103774A patent/AR050638A1/es not_active Application Discontinuation
2007
- 2007-02-20 IL IL181445A patent/IL181445A/en active IP Right Grant
- 2007-04-04 NO NO20071792A patent/NO338713B1/no unknown
2010
- 2010-09-07 CY CY20101100816T patent/CY1110770T1/el unknown
- 2010-11-04 US US12/939,726 patent/US20110184068A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DK1809271T3 (da)	2010-09-20
EP1809271B9 (en)	2010-09-22
AU2005282028B2 (en)	2011-03-24
HRP20100400T1 (hr)	2010-09-30
WO2006027052A2 (en)	2006-03-16
US20080096965A1 (en)	2008-04-24
ME01801B (me)	2011-02-28
RS51411B (sr)	2011-02-28
IL181445A (en)	2014-03-31
RU2391973C2 (ru)	2010-06-20
HK1105359A1 (en)	2008-02-15
CA2577408C (en)	2013-07-09
CN101018546A (zh)	2007-08-15
AU2005282028A2 (en)	2006-03-16
DK1809271T5 (da)	2010-12-06
CA2577408A1 (en)	2006-03-16
DE602005021907D1 (de)	2010-07-29
ES2347581T3 (es)	2010-11-02
NO338713B1 (no)	2016-10-03
SI1809271T1 (sl)	2010-10-29
AU2005282028A1 (en)	2006-03-16
RU2007113190A (ru)	2008-10-27
CY1110770T1 (el)	2015-06-10
JP2008512405A (ja)	2008-04-24
NZ553970A (en)	2010-01-29
JP5319920B2 (ja)	2013-10-16
KR20070061863A (ko)	2007-06-14
KR101277520B1 (ko)	2013-06-21
NO20071792L (no)	2007-06-11
EP1809271A2 (en)	2007-07-25
AR050638A1 (es)	2006-11-08
TW200612894A (en)	2006-05-01
TWI351950B (en)	2011-11-11
US20110184068A1 (en)	2011-07-28
ATE471147T1 (de)	2010-07-15
IL181445A0 (en)	2007-07-04
WO2006027052A3 (en)	2006-05-26
CN101018546B (zh)	2013-06-12
BRPI0515154A (pt)	2008-07-08
PT1809271E (pt)	2010-08-30
MX2007002713A (es)	2007-05-23
EP1809271B1 (en)	2010-06-16

Publication	Publication Date	Title
EP1773826A4 (en)	2009-06-03	MODULATORS OF C-MET AND THEIR METHOD OF USE
AU2003230401A8 (en)	2003-11-11	Bis-benzimidazoles and related compounds as potassium channel modulators
EP1874759A4 (en)	2009-07-15	C-MET MODULATORS MODULATORS AND METHODS OF USE
IL178564A0 (en)	2007-02-11	Improved modulators of coagulation factors
IL181445A0 (en)	2007-07-04	Use of (halobenzyloxy)benzylamino-propanamides for the manufacture of medicaments active as sodium and/or calcium selective modulators
EP1855598A4 (en)	2014-03-26	METHOD AND DEVICES FOR ANCHORING IN SOFT TISSUE
IL176958A0 (en)	2006-12-10	Compounds and methods of use
AU2003298786A8 (en)	2004-06-18	Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
EP1751124A4 (en)	2010-04-14	RAF MODULATORS AND METHODS OF USE
GB2427980B (en)	2007-10-10	Means and method of allocating channel bandwidth
EP1610774A4 (en)	2008-07-16	TIE-2 MODULATORS AND METHODS OF USE
EP1611123A4 (en)	2008-07-02	TIE-2 MODULATORS AND METHOD OF USE
AU2003259717A8 (en)	2004-02-25	Modulators of rabggt and methods of use thereof
ZA200707085B (en)	2009-05-27	Tetracyclic amino and carboxamido compounds and methods of use thereof
EP1722783A4 (en)	2009-08-12	MODULATORS OF THE ION CHANNEL FUNCTION
PL1963280T3 (pl)	2016-04-29	Pochodne 2-fenyloetyloaminowe jako modulatory kanału wapniowego i/lub sodowego
GB2417955B (en)	2008-09-24	Asymmetric benzimidazoles and related compounds as potassium channel modulators
GB0403889D0 (en)	2004-03-24	Uses of er-beta modulators
EP1608373A4 (en)	2010-09-29	TIE-2 MODULATORS AND USE METHOD
GB0400775D0 (en)	2004-02-18	Gel composition
AU2003216354A8 (en)	2003-09-09	Modulators of paraptosis and related methods
SG108958A1 (en)	2005-02-28	Bridged carbocyclic compounds and methods of making and using same
GB2389654B (en)	2004-05-26	Sodium channel regulators and modulators
IL177647A0 (en)	2007-07-04	Use of enzyme
GB0320842D0 (en)	2003-10-08	Ion channel modulators